SOS1::KRAS Inhibitor
Oncology (KRAS-driven cancers)
Discovery/PreclinicalActive (Collaborative)
Key Facts
Indication
Oncology (KRAS-driven cancers)
Phase
Discovery/Preclinical
Status
Active (Collaborative)
Company
About Schrodinger
Schrödinger is a computational science pioneer with a dual-business model combining high-margin software licensing with internal drug discovery. Founded in 1990, the company has built a sophisticated, physics-based platform that is widely adopted by pharmaceutical and materials science organizations. Its strategy validates its technology through internal deployment in a therapeutic pipeline, aiming to create diversified revenue streams and capture value across the discovery value chain.
View full company profileTherapeutic Areas
Other Oncology (KRAS-driven cancers) Drugs
| Drug | Company | Phase |
|---|---|---|
| KRAS (G12D)/cRAF/CYPA/Inhibitor Assay Kit | Aurora Biolabs | Commercial |